Venous thromboembolism (VTE) is rare in young women but is associated with the use of
combined oral contraceptives (OCs). In 1995 and 1996, three studies showed a difference in …

New epidemiological studies have demonstrated a higher risk of venous thromboembolism
among users of oral contraceptives (O Cs) with third-generation progestogens desogestrel …

The objective of this study was to assess the influence of oral contraceptives (OCs) on the
risk of venous thromboembolism (VTE) in young women. A 5-year case-control study …

Controversy exists regarding whether oral contraceptives (OCs) containing desogestrel and
gestodene are associated with an increased risk of venous thromboembolism (VTE) versus …

CONTEXT: Previous studies have reported that users of the “third-generation” oral
contraceptives (OCs) containing the progestins gestodene and desogestrel have about …

To assess the influence of oral contraceptives (OC) on the risk for venous thromboembolism
(VTE) in young women, a 5-year case-control study including all women 15–44 years old …

Abstract In October 1995 the Committee on Safety of Medicines advised UK doctors and
pharmacists that oral contraceptives containing desogestrel and gestodene were associated …

PIP: New studies linking use of oral contraceptives (OCs) containing a third generation
progestogen with venous thromboembolism (VTE) have stirred controversy. Epidemiologists …

Background Four studies published since December, 1995, reported that the incidence of
venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) …

A matched case-control study was undertaken in 10 centers in Germany and the United
Kingdom to explore the association of current use of major combination oral contraceptives …